![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H25FN2O3 |
Molar mass | 396.462 g·mol−1 |
3D model (JSmol) | |
| |
|
MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. [1]
It was first detected by the EMCDDA in Sweden in February 2015. [2] It is often sold in e-liquid form for use in an electronic cigarette. [3]
MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015. [4]
MDMB-FUBICA is banned in Sweden. [5]